270 related articles for article (PubMed ID: 18332267)
1. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
Roy D; Pratt CM; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Nielsen T; Rasmussen SL; Stiell IG; Coutu B; Ip JH; Pritchett EL; Camm AJ;
Circulation; 2008 Mar; 117(12):1518-25. PubMed ID: 18332267
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
Beatch GN; Mangal B
BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
[TBL] [Abstract][Full Text] [Related]
4. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.
Camm AJ; Toft E; Torp-Pedersen C; Vijayaraman P; Juul-Moller S; Ip J; Beatch GN; Dickinson G; Wyse DG;
Europace; 2012 Jun; 14(6):804-9. PubMed ID: 22291438
[TBL] [Abstract][Full Text] [Related]
6. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
Beatch GN; Bhirangi K; Juul-Moller S; Rustige J
J Cardiovasc Pharmacol; 2017 Feb; 69(2):86-92. PubMed ID: 27828791
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
Stiell IG; Roos JS; Kavanagh KM; Dickinson G
Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
[TBL] [Abstract][Full Text] [Related]
10. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
[TBL] [Abstract][Full Text] [Related]
11. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
Torp-Pedersen C; Camm AJ; Butterfield NN; Dickinson G; Beatch GN
Int J Cardiol; 2013 Jun; 166(1):147-51. PubMed ID: 22108512
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
[TBL] [Abstract][Full Text] [Related]
13. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Camm AJ; Capucci A; Hohnloser SH; Torp-Pedersen C; Van Gelder IC; Mangal B; Beatch G;
J Am Coll Cardiol; 2011 Jan; 57(3):313-21. PubMed ID: 21232669
[TBL] [Abstract][Full Text] [Related]
14. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
Lévy S; Hartikainen J; Ritz B; Juhlin T; Carbajosa-Dalmau J; Domanovits H
Cardiovasc Drugs Ther; 2021 Apr; 35(2):283-292. PubMed ID: 33206300
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs Aging; 2011 Jun; 28(6):501-4. PubMed ID: 21639409
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
Ma W; Guo X; Wang Q; Sun G; Wang J
J Cardiovasc Pharmacol; 2020 Jul; 76(1):32-41. PubMed ID: 32251022
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
Savelieva I; Graydon R; Camm AJ
Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Tsuji Y; Dobrev D
Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
[TBL] [Abstract][Full Text] [Related]
19. Vernakalant: A novel agent for the termination of atrial fibrillation.
Finnin M
Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
[TBL] [Abstract][Full Text] [Related]
20. Vernakalant in the management of atrial fibrillation.
Cheng JW
Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
